1,245 results match your criteria: "Christ Hospital[Affiliation]"
Understanding older adults' perceptions of hospital falls: Confidence, fear, consequences, and help-seeking intentions.
Geriatr Nurs
December 2024
The Catholic University of America, Miami University, and The Christ Hospital, United States.
Aim: Aim of the paper is to determine the relationship between patients' perceived risk of falling and their fall-risk assessment ranking.
Design: A cross-sectional correlational design.
Methods: Four questionnaires: confidence, fear, consequence and intention related to falls were administered to 54 hospitalized older adults.
Rationale and Design of the Personalized Therapy Study: Evaluating Real-World Performance of Two Automated Defibrillation Therapy Algorithms.
J Card Fail
December 2024
The Heart and Vascular Center at The Christ Hospital, Cincinnati, OH, USA. Electronic address:
Background: Barriers to maximizing patient benefit with implantable defibrillation devices include limited ability to tailor antitachycardia pacing (ATP) therapy in real-time and identify patients at risk of heart failure (HF) events early on. The Personalized Therapy study aims to evaluate the performance of two algorithms, intrinsic ATP (iATP) and TriageHF, to address these barriers in routine clinical practice.
Methods And Results: The Personalized Therapy Study was designed as a prospective, multicenter, post-market registry study expected to enroll approximately 2,200 patients meeting the following criteria: (1) implanted with a study-eligible device regardless of procedure type; (2) Medtronic CareLink® Network enrolled; (3) TriageHF enabled within CareLink and High Risk Alert notifications turned ON; and (4) iATP enabled.
Calcified plaque modification during percutaneous coronary revascularization.
Prog Cardiovasc Dis
December 2024
The Christ Hospital Heart & Vascular Institute and The Carl and Edyth Lindner Center for Research and Education, Cincinnati, Ohio, USA.. Electronic address:
The presence and severity of calcified coronary plaque negatively impacts angiographic and clinical outcomes following percutaneous coronary intervention (PCI). Severe coronary calcification is associated with suboptimal stent delivery, deployment, apposition and expansion which can lead to in-stent restenosis and/or thrombosis. Severe coronary calcification is associated with incremental hazard for adverse clinical events, including death, during 5-10 years following PCI despite the use of new generation drug- eluting stents.
View Article and Find Full Text PDFThe Revolution of STEMI Care: A Story of Resilience, Persistence, and Success.
J Soc Cardiovasc Angiogr Interv
November 2024
Northside Hospital Heart Institute, Atlanta, Georgia.
SCAI Expert Consensus Statement on the Management of Patients With STEMI Referred for Primary PCI.
J Soc Cardiovasc Angiogr Interv
November 2024
Minneapolis Heart Institute, Abbott Northwestern Hospital, and Center for Coronary Artery Disease, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota.
ST-elevation myocardial infarction (STEMI) remains a leading cause of morbidity and mortality in the United States. Timely reperfusion with primary percutaneous coronary intervention is associated with improved outcomes. The Society for Cardiovascular Angiography & Interventions puts forth this expert consensus document regarding best practices for cardiac catheterization laboratory team readiness, arterial access with an algorithm to help determine proper arterial access in STEMI, and diagnostic angiography.
View Article and Find Full Text PDFThe Effect of Reverse Shoulder Arthroplasty Design and Surgical Indications on Deltoid and Rotator Cuff Muscle Length.
J Shoulder Elbow Surg
December 2024
New England Baptist Hospital, Boston, MA, USA; Boston Sports and Shoulder Center Research Foundation, Waltham, MA, USA. Electronic address:
Background: Advancements in surgical planning, technique, and prosthesis design have improved adaptation to patient anatomy in reverse total shoulder arthroplasty (rTSA). Postoperative changes in deltoid and rotator cuff muscle length are important and may vary based on preoperative indications and prosthesis selection. The purpose of this study is to demonstrate the changes in deltoid and rotator cuff muscle length for planned rTSA using the spectrum of prosthesis configurations in both GHOA and RCA.
View Article and Find Full Text PDFHospital readmissions following catheter ablation for atrial fibrillation with THERMOCOOL™ STSF/ THERMOCOOL™ ST catheter with CARTO™ 3 system versus TactiCath™ catheter with EnSite™ system.
J Comp Eff Res
January 2025
MedTech Epidemiology & Real-World Data Science, Johnson & Johnson, New Brunswick, NJ, USA.
Radiofrequency (RF) catheter ablation (CA) is a mainstay treatment for atrial fibrillation (AF). RF catheters with contact force (CF) sensing technology and electroanatomical mapping systems enable real-time assessment of catheter tip-tissue interface CF, facilitating individualized and precise CA. This study examined inpatient hospital readmissions in patients with AF treated with THERMOCOOL™ ST/ THERMOCOOL™ STSF catheter with the CARTO™ 3 System versus TactiCath™ catheter with the EnSite™ System.
View Article and Find Full Text PDFArticle Synopsis
- There is currently no FDA-approved dedicated transcatheter heart valve specifically for treating native aortic regurgitation.
- Ongoing clinical trials and compassionate use experiences in the U.S. offer some outcomes data, focusing on echocardiographic and clinical results one year post-procedure.
- A case study of a 28-year-old man treated with the J-Valve in 2019 shows promising long-term (5-year) outcomes, suggesting it could be a viable minimally invasive option for high-risk patients.
A Dedicated Transcatheter Heart Valve for Native Aortic Regurgitation in Patients With Significant Aortic Angulation.
JACC Case Rep
November 2024
Carl & Edyth Lindner Center for Research and Education, The Christ Hospital Heart & Vascular Institute, Cincinnati, Ohio, USA.
Article Synopsis
- * The J-Valve device, developed by JC Medical, shows promising outcomes, particularly in patients with complex anatomical challenges.
- * Two successful cases of transcatheter aortic valve replacement using the J-Valve were reported in patients who had significant aortic angulation.
Outcomes of coronary intravascular lithotripsy for the treatment of calcified nodules: a pooled analysis of the Disrupt CAD studies.
EuroIntervention
December 2024
St. Francis Hospital, Roslyn, NY, USA.
Article Synopsis
- Coronary intravascular lithotripsy (IVL) is an effective method for stent implantation in severely calcified lesions, specifically those with calcified nodules (CNs).
- In a study of 155 patients, IVL demonstrated similar outcomes in terms of stent area and expansion, regardless of the presence of CNs, even though CNs had higher calcium volume and angle.
- The 2-year rate of target lesion failure was not significantly different between CN and non-CN lesions, suggesting that further research is needed to evaluate different treatment methods for these types of lesions.
Results of SurVeil Versus IN.PACT Admiral Paclitaxel Coated Balloons in Femoropopliteal Arteries: Outcomes of the Randomised TRANSCEND Study Through 24 Months.
Eur J Vasc Endovasc Surg
November 2024
Vascular Medicine and Intervention, Massachusetts General Hospital, Boston, MA, USA.
Article Synopsis
- * In this randomized controlled trial involving 446 patients, the SurVeil PCB showed a primary safety rate of 91.8% and a primary efficacy rate of 82.2%, while the IN.PACT Admiral had rates of 89.8% and 85.9%, respectively.
- * The results indicate that the SurVeil PCB is a safe and effective treatment option, demonstrating non-inferiority to the IN.PACT Admiral PCB over a 24-month period.
Use of Intravascular Micro-Axial Left Ventricular Assist Devices as a Bridging Strategy for Cardiogenic Shock: Mid-Term Outcomes.
J Clin Med
November 2024
Heart and Vascular Institute, Pennsylvania State Milton S Hershey Medical Center, Hershey, PA 17033, USA.
: Patients in cardiogenic shock (CS) may be successfully bridged using intravascular micro-axial left ventricular assist devices (M-LVADs) for recovery or determination of definitive therapy. : One hundred and seven CS patients implanted with M-LVADs from January 2020 to May 2024 were divided into four groups; group-1: 34 patients (transplant); group-2: 25 patients (LVAD); group-3: 42 patients (postcardiotomy CS (PCCS)); group-4: 6 patients (decision/recovery but excluded from analysis). Multivariable logistic regression and Multivariable Coxregression models identified predictors of early -hospital and late mortality, and Odds ratios (ORs) and hazard ratios (HRs) with < 0.
View Article and Find Full Text PDFMesenchymal precursor cells reduce mortality and major morbidity in ischaemic heart failure with inflammation: DREAM-HF.
Eur J Heart Fail
November 2024
Division of Cardiology, University of California, San Diego, CA, USA.
Article Synopsis
- The study investigates how bone marrow-derived pro-inflammatory macrophages and embryo-derived reparative macrophages impact progressive heart failure with reduced ejection fraction (HFrEF) and explores the potential of mesenchymal precursor cells (MPCs) to improve patient outcomes.
- In the DREAM-HF trial, significant risk factors for cardiovascular death (CVD) were identified in patients with HFrEF, particularly inflammation and ischaemic aetiology, which increased the risk by 61% and 38%, respectively.
- The introduction of MPCs led to notable reductions in major adverse cardiovascular events (MACE) by 88% and 52% over a 30-month follow-up in patients with ischaemic HFrEF and inflammation.
When Is It a Bridge Too Far?
J Soc Cardiovasc Angiogr Interv
September 2024
The Carl and Edyth Lindner Center for Research and Education, The Christ Hospital, Cincinnati, Ohio.
Colchicine in Acute Myocardial Infarction.
N Engl J Med
November 2024
From the Population Health Research Institute, McMaster University (S.S.J., M.-A.E., S.F.L., R. Mian, J.T., S.R.M., P.J.D., J.E., T.S., D.C., S.T., S.Y.), and Hamilton Health Sciences (S.S.J., M.-A.E., S.F.L., R. Mian, S.R.M., P.J.D., J.E., T.S., D.C.), Hamilton, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke (M.-A.E.), the University of British Columbia and Centre for Cardiovascular Innovation, Vancouver Coastal Health, Vancouver (J.A.C.), the Department of Medicine, University of Saskatchewan, Saskatoon (W.T.), and London Health Sciences, University of Western Ontario, London (S.L.) - all in Canada; the University Clinic of Cardiology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, North Macedonia (S.K., B.Z.); Sorbonne University, ACTION Study Group, Centre Hospitalier Universitaire Pitié-Salpêtrière Assistance Publique-Hopitaux de Paris, Paris (G.M.); the Dutch Network for Cardiovascular Research, Utrecht, Radboud University Medical Center, Nijmegen, and Northwest Clinics, Alkmaar - all in the Netherlands (J.H.C.); the University Clinical Center of Serbia and the Faculty of Medicine, University of Belgrade, Belgrade (G.S.); the Cardiology Department, University Hospital La Paz, Universidad Autónoma de Madrid, Madrid (R. Moreno); NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, and the Division of Clinical Medicine, University of Sheffield - both in Sheffield, United Kingdom (R.F.S.); the Caril and Edyth Lindner Center for Research and Education, Christ Hospital Health Network, Cincinnati (T.D.H.); the Cardiology Division, Heart Center, Luzerner Kantonsspital, and the Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland (M.B.); University Hospital Brno, Brno, Czech Republic (P.K.); the Department of Cardiology, Peninsula Health, Frankston, VIC, and Peninsula Clinical School, Central Clinical School, Monash University, Melbourne, VIC - both in Australia (J.L.); the Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, and the Section of Cardiology, Department of Medicine, VA New York Harbor Healthcare System, New York (B.S.); and B.P. Koirala Institute of Health Sciences, Dharan, Nepal (S.K.S.).
Article Synopsis
- * A total of 7062 patients participated, and the results showed no significant difference in primary cardiovascular outcomes between the colchicine group (9.1%) and the placebo group (9.3%) over a 3-year follow-up period.
- * Colchicine did lower C-reactive protein levels, indicating some anti-inflammatory effect, but it also caused more diarrhea compared to placebo, though serious infections were similar in both groups.
Left Atrial Appendage Closure after Ablation for Atrial Fibrillation.
N Engl J Med
November 2024
From Cleveland Clinic, Cleveland (O.M.W., W.I.S., K.W.); St. Bernards Medical Center and Arrhythmia Research Group, Jonesboro, AR (D.G.N.); the Cardiology Department, European Georges Pompidou Hospital, Paris (E.M.); Cardioangiologisches Centrum Bethanien, Agaplesion Markus Krankenhaus, Frankfurt am Main (B.S.), Catholic Hospital, Sankt Johann Nepomuk, Erfurt (H.E.), and Deutsches Herzzentrum der Charité (DHZC), Campus Benjamin Franklin, Berlin (C.S.) - all in Germany; Iowa Heart Center, West Des Moines (T.H.); Ascension St. Vincent's Medical Center, Jacksonville, FL (S.O.); UPMC Pinnacle, Harrisburg, PA (C.P.); Vanderbilt University, Nashville (A.K.); Phoenix Cardiovascular Research Group, Phoenix AZ (A.S.); South Denver Cardiology, Littleton, CO (S.S.); Grandview Medical Center, Birmingham, AL (J. Osorio); Heart House-Cooper University, Camden, NJ (G.M.); Lindner Center for Research and Education at Christ Hospital, Cincinnati (M.G.); Emory University, Medicine, Atlanta (D.B.D.); St. Vincent Heart Center of Indiana, Indianapolis (J. Olson); the Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark (J.E.N.-K.); St. Antonius Hospital, Nieuwegein, the Netherlands (L.V.A.B.); the Population Health Research Institute, Hamilton, ON, Canada (J.S.H.); Brisbane AF Clinic, Greenslopes Private Hospital, Brisbane, QLD, Australia (K.P.P.); Medstar Health Research Institute, Medstar Washington Hospital Center, Washington, DC (F.M.A.); Boston Scientific, Marlborough, MA (K.R., T.C., B.S.S., K.M.S.); and Cardiac Electrophysiology, Mount Sinai Fuster Heart Hospital School of Medicine, New York (V.Y.R.).
Background: Oral anticoagulation is recommended after ablation for atrial fibrillation among patients at high risk for stroke. Left atrial appendage closure is a mechanical alternative to anticoagulation, but data regarding its use after atrial fibrillation ablation are lacking.
Methods: We conducted an international randomized trial involving 1600 patients with atrial fibrillation who had an elevated score (≥2 in men and ≥3 in women) on the CHADS-VASc scale (range, 0 to 9, with higher scores indicating a greater risk of stroke) and who underwent catheter ablation.
Routine Spironolactone in Acute Myocardial Infarction.
N Engl J Med
November 2024
From the Population Health Research Institute, McMaster University (S.S.J., M.-A.E., S.F.L., R. Mian, J.T., S.R.M., P.J.D., J.E., M.K.N., J.D.S., D.C., S.T., S.Y.), and Hamilton Health Sciences (S.S.J., M.-A.E., S.F.L., R. Mian, S.R.M., P.J.D., J.E., M.K.N., J.D.S., D.C.), Hamilton, ON, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC (M.-A.E.), the University of British Columbia and Centre for Cardiovascular Innovation, Vancouver Coastal Health, Vancouver (J.A.C.), the Department of Medicine, University of Saskatchewan, Moose Jaw (W.T.), London Health Sciences Centre, University of Western Ontario, London (S.L.), Southlake Regional Health Centre, Newmarket, University of Toronto, Toronto (W.J.C.), Quebec Heart-Lung Institute, Laval University, Quebec, QC (O.F.B.), and St. Mary's Hospital, Kitchener, ON (A.P.) - all in Canada; the University of Michigan, Ann Arbor (B.P.); the Medical Faculty, University Clinic of Cardiology, University Ss. Cyril and Methodius, Skopje, North Macedonia (S.K., B.Z.); Sorbonne University, ACTION Study Group, Centre Hospitalier Universitaire Pitié-Salpêtrière Assistance Publique-Hôpitaux de Paris, Paris (G.M.); Dutch Network for Cardiovascular Research, Utrecht, Radboud University Medical Center, Nijmegen, and Northwest Clinics, Alkmaar - all in the Netherlands (J.H.C.); University Clinical Center of Serbia and the Faculty of Medicine, University of Belgrade (G.S.), and Institut za Kardiovaskularne Bolesti Dedinje-Belgrade (D.T.) - all in Belgrade; the Cardiology Department, University Hospital La Paz, Madrid (R. Moreno); NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, and the Division of Clinical Medicine, University of Sheffield, Sheffield - both in the United Kingdom (R.F.S.); the Caril and Edyth Lindner Center for Research and Education, Christ Hospital Health Network, Cincinnati (T.D.H.); the Cardiology Division, Heart Center, Luzerner Kantonsspital, and the Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland (M.B.); University Hospital Brno, Brno, Czech Republic (P.K.); the Department of Cardiology, Peninsula Health, Frankston, VIC, and Peninsula Clinical School, Central Clinical School. Monash University, Melbourne, VIC - both in Australia (R.B.); B.P. Koirala Institute of Health Sciences, Dharan, Nepal (S.K.S.); and Clinical Hospital Tetovo, Tetovo, North Macedonia (V.A.).
Background: Mineralocorticoid receptor antagonists have been shown to reduce mortality in patients after myocardial infarction with congestive heart failure. Whether routine use of spironolactone is beneficial after myocardial infarction is uncertain.
Methods: In this multicenter trial with a 2-by-2 factorial design, we randomly assigned patients with myocardial infarction who had undergone percutaneous coronary intervention to receive either spironolactone or placebo and either colchicine or placebo.
Utilizing Invasive Coronary Functional Testing in a Coronary Microvascular and Vasomotor Dysfunction Program: Methods and Considerations.
Catheter Cardiovasc Interv
December 2024
Carl and Edyth Lindner Center for Research and Education, The Christ Hospital Health Network, Cincinnati, Ohio, USA.
Background: Coronary microvascular and vasomotor dysfunction (CMVD) is associated with a threefold increased risk of major adverse cardiovascular events (MACE) and is the primary mechanism responsible for angina/ischemia in patients with nonobstructive coronary artery disease (ANOCA/INOCA). Proper assessment for CMVD is vital to provide targeted treatment and improve patient outcomes. Invasive coronary functional testing (ICFT) is the "gold standard," for CMVD assessment and can be used to diagnose all endotypes.
View Article and Find Full Text PDFClinical Outcomes and Practicality of Transferring Patients Immediately to Originating Hospitals After Primary Percutaneous Coronary Intervention-A Retrospective Study.
Catheter Cardiovasc Interv
January 2025
Cardiology Department, Hospital Sultan Idris Shah, Serdang, Malaysia.
Background: Primary Percutaneous Coronary Intervention (PPCI) is the preferred treatment for ST-Segment Elevation Myocardial Infarction (STEMI) patients in both PCI centers and those transferred from non-PCI centers, provided it can be performed in a timely manner. The challenges in transferring patients from non-PCI centers include not only potential delays beyond 120 min but also the risk of overwhelming the resources at the PPCI hospital. We report a novel strategy implemented within the Serdang STEMI Network involving immediate transfer of patients back to the originating hospitals within 2 h post procedure.
View Article and Find Full Text PDFTranscaval access for transcatheter aortic valve implantation: A meta-analysis and systematic review.
Int J Cardiol
January 2025
Department of Cardiology, Mayo Clinic, Phoenix, AZ, United States of America.
Background: Anatomical factors may preclude transfemoral (TF) arterial access for transcatheter aortic valve implantation (TAVI). Transcaval (TCav) access has been utilized as an alternative access for these patients. We aimed to investigate the outcomes of TCav access in patients undergoing TAVI.
View Article and Find Full Text PDFHeart Transplantation Outcomes in Patients With Hypertrophic Cardiomyopathy in the Era of Mechanical Circulatory Support.
ASAIO J
November 2024
Division of Cardiology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Mechanical circulatory support has emerged as a vital therapeutic modality for patients awaiting heart transplantation (HT). However, it is unknown how it affected the characteristics and post-HT outcomes of patients with hypertrophic cardiomyopathy (HCM). This retrospective cohort study analyzed adult HT recipients from the International Society for Heart and Lung Transplantation registry (1998-2017).
View Article and Find Full Text PDFDeveloping a Women's Heart Center With a Specialization in Coronary Microvascular and Vasomotor Dysfunction: If You Build It, They Will Come.
Catheter Cardiovasc Interv
December 2024
Women's Heart Center, Heart & Vascular Institute, The Christ Hospital Health Network, Cincinnati, Ohio, USA.
Background: Women's Heart Centers (WHC) are comprehensive, multidisciplinary care centers designed to close the existing gap in women's cardiovascular care. The WHC at The Christ Hospital Heart and Vascular Institute (TCH-WHC) in Cincinnati, Ohio was established in October of 2020, and is a specialized coronary microvascular and vasomotor dysfunction (CMVD) program.
Methods: The TCH-WHC focuses its efforts across five pillars: patient care, research, education, community outreach and advocacy, and grants and philanthropy.
Use of radiofrequency ablation of the vaginal canal for genitourinary syndrome of menopause.
J Sex Med
January 2025
Division of Female Pelvic Medicine and Reconstructive Surgery, The Christ Hospital, 6939 Cox Rd, Suite 271, Liberty Township, OH, United States.
Background: Genitourinary syndrome of menopause (GSM) is a prevalent condition with a constellation of symptoms including burning, dryness, dyspareunia, and irritative lower urinary tract symptoms that result from vulvovaginal atrophic changes. Though hormonal therapy is a mainstay of treatment in GSM, some patients may pursue nonhormonal therapies.
Aim: To determine the efficacy of radiofrequency ablation of the vaginal canal with the MorpheusV applicator in reducing the symptoms of GSM.
Validation of the coronary artery specific chronic total occlusion percutaneous coronary intervention angiographic difficulty scores in the PROGRESS-CTO registry.
Cardiovasc Revasc Med
October 2024
Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN, USA. Electronic address:
Background: The J-CTO investigators recently developed angiographic difficulty scores for each of the three major coronary arteries in patients undergoing first-attempt chronic total occlusion (CTO) percutaneous coronary intervention (PCI) in de novo occlusions.
Methods: We examined the performance of the individual J-CTO scores in a large multicenter registry.
Results: The CTO lesion location was as follows: right coronary artery (RCA) 3,805 (54%), left anterior descending artery (LAD) 2,303 (33%), and left circumflex (LCX) 935 (13%).
Association of Dialysate Bicarbonate with Arrhythmia in the Monitoring in Dialysis Study.
Kidney360
October 2024
Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Article Synopsis
- Sudden death is a significant concern for hemodialysis patients, accounting for about 25% of their deaths, with more incidents occurring on the days they receive treatment.
- A study analyzed data from 66 patients using implantable loop recorders over 12 months to examine how higher levels of dialysate bicarbonate (DBIC) affected the occurrence of serious heart arrhythmias.
- The results showed that while fewer episodes of clinically significant arrhythmia were linked to DBIC levels over 35 mEq/L, this finding lost significance when factoring in potassium levels, highlighting the need for further research with larger sample sizes.